Switchpoint Bio raises €4.75M for blood-based epigenomics

What the platform does

According to the company, the platform gives drug developers a scalable view of how disease and treatment change human biology. It does this through blood tests that read epigenomic signals, the layer of biological regulation that reflects how genes are being used rather than the underlying DNA sequence itself.

For pharmaceutical and biotech teams, a blood-based readout is attractive because samples are comparatively easy to collect. That could make it simpler to track how patients respond to a therapy over time, and to understand disease mechanisms, without relying on more invasive procedures.

Why it matters

Understanding why some patients respond to a drug and others do not remains one of the central challenges in drug development. Tools that capture disease and drug response at scale from routine samples could help companies make better decisions earlier in the process.

Switchpoint Bio's dual base in Finland and the Boston area, a major life-sciences hub, places it in two research ecosystems. Further details on the product, customers and timelines were not part of the announcement.